Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (27148)	1/4/1999 3:10:00 PM
From: j g cordes	Read Replies (1) \| Respond to of 32384

Nice post Cheryl, sometimes finding old news awakens one's thoughts on the present.

To: Cheryl Galt who wrote (27148)	1/4/1999 5:10:00 PM
From: aknahow	Respond to of 32384

From an old LGND press release July 98, (97)? Milestone and royalty payments for droloxifene are contingent upon droloxifene's advancement toward regulatory approval and sales as a drug in breast cancer, osteoporosis or other indications. The royalty rate will be 1% on droloxifene worldwide sales for breast cancer. If Pfizer makes sales of droloxifene for any indication other than breast cancer, including osteoporosis, the royalty will then be 3% for all indications. First I was pleased by LGND having provided the royalty information then I was shocked that it was so low. Reminds me that partnership agreements are not always the great deals some think they are. I am sure all frequent posters remember this press release but for me, even though old, I saw it with a new light. I have trouble with the on line LGND corporate site. Is there anything really there?